Abstract
Background:The aim of this study was to more precisely map the region of 16q loss of heterozygosity (LOH) in Wilms’ tumors and to examine the expression of putative tumor suppressor.
Methods:We performed polymerase chain reaction–based LOH analysis on the 185 sample pairs from 21 to 80 megabases (Mb) on chromosome 16q. Expression of two candidate tumor suppressor genes located within the identified consensus region of 16q LOH was examined by immunohistochemistry.
Results:We identified 16q LOH in 7 (4%) of 185 Wilms’ tumors not previously thought to demonstrate such genetic loss. The smallest common region of genetic loss was located between 67.3 and 74.0 Mb on chromosome 16. Within this 6.7-Mb region, there reside only three recognized tumor suppressor genes: E-cadherin, P-cadherin, and E2F4. E-cadherin demonstrates statistically significantly reduced expression in Wilms’ tumors with 16q LOH.
Conclusions:We have localized the consensus region of 16q LOH in Wilms’ tumor to a 6.7-Mb locus and have identified three candidate Wilms’ tumor suppressor genes within this narrowed region. Our data support E-cadherin as a candidate tumor suppressor gene in Wilms’ tumor; however, further studies are needed to definitively prove its role as the tumor suppressor gene associated with 16q LOH.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Slater R, Mannens M. Cytogenetics and molecular genetics of Wilms’ tumor of childhood. Cancer Genet Cytogenet 1992; 61: 111–21.
Mason JE, Goodfellow PG, Grundy PE, Skinner MA. 16q loss of heterozygosity and microsatellite instability in Wilms’ tumor. J Pediatr Surg 2000; 35: 891–7.
Wadey RB, Pal N, Buckle B, Yeomans E, Pritchard J, Cowell JK. Loss of heterozygosity in Wilms’ tumour involves two distinct regions of chromosome 11. Oncogene 1990; 5: 901–7.
Koufos A, Grundy PE, Morgan K, et al. Familial Weidemann-Beckwith syndrome and a second Wilms’ tumor locus both map to 11p15.5. Am J Hum Genet 1989; 44: 711–9.
Fearon E, Vogelstein B, Feinberg AP. Somatic deletion and duplication of genes on chromosome 11 in Wilms’ tumors. Nature 1984; 309: 176–8.
Maw MA, Grundy PE, Millow LJ, et al. A third Wilms’ tumor locus on chromosome 16q. Cancer Res 1992; 52: 3094–8.
Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V, Paterson MC. Loss of heterozygosity for chromosome 16q and 1p in Wilms’ tumors predicts an adverse outcome. Cancer Res 1994; 54: 2331–3.
Grundy PE, Telzerow PE, Moksness J, Breslow NE. Clinicopathologic correlates of loss of heterozygosity for chromosome 16q and 1p in Wilms’ tumor: a preliminary analysis. Med Pediatr Oncol 1996; 27: 429–33.
Grundy RG, Pritchard J, Scrambler P, Cowell JK. Loss of heterozygosity on chromosome 16 in sporadic Wilms’ tumor. Br J Cancer 1998; 78: 1181–7.
Becker K, Atkinson M, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994; 54: 3845–53.
Soler AP, Knudsen KA, Salazar H, Han AC, Keshgegian AA. P-cadherin expression in breast carcinoma indicates poor survival. Cancer 1999; 86: 1263–72.
Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol 1998; 153: 333–9.
Graff JR, Gabrielson E, Fuji H, Baylin SB, Herman JG. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000; 275: 2727–32.
Bringuier P, Umbas R, Schaafsma H, Karthaus H, Debruyne F, Schalken J. Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res 1993; 53: 3241–5.
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93: 9821–6.
Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997; 272: 22322–22329.
Klamt B, Schulze M, Thate C, et al. Allele loss in Wilms tumors of chromosome arms 11q, 16q, and 22q correlates with clinicopathological parameters. Genes Chromosomes Cancer 1998; 22: 287–94.
Schulz S, Becker K-F, Braungart E, et al. Molecular analysis of E-cadherin and cadherin-11 in Wilms’ tumours. J Pathol 2000; 191: 162–9.
Liotta L, Steeg P, Stetler-Stevenson W. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327–36.
Behrens J, Mareel M, Van Roy F, Birchmeier W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. J Cell Biol 1989; 108: 2435–47.
Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms’ tumors. Cancer Res 1999; 59: 3880–2.
Matsumura T, Makino R, Mitamura K. Frequent down-regulation of E-cadherin by genetic and epigenetic changes in the malignant progression of hepatocellular carcinomas. Clin Cancer Res 2001; 7: 594–9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Safford, S.D., Goyeau, D., Freemerman, A.J. et al. Fine Mapping of Wilms’ Tumors With 16q Loss of Heterozygosity Localizes the Putative Tumor Suppressor Gene to a Region of 6.7 Megabases. Ann Surg Oncol 10, 136–143 (2003). https://doi.org/10.1245/ASO.2003.03.038
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2003.03.038